Johnson & Johnson (JNJ) stock had a bullish inflow of $222.43 million worth of trades on uptick and an outflow of $114.14 million in downticks on Friday. The total uptick to downtick ratio stood at 1.95. The net money flow into the stock was $108.3 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $101.87 million. An inflow of $29.52 million block trade was recorded on downticks. $131.39 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. The total uptick to downtick ratio of block trades was 4.45 in favor of the bulls. However, Johnson & Johnson (JNJ) stock traded down $0.12 , and reached $125.03, a drop of -0.1% over the previous day. On a weekly basis, the stock is 1.65%, over the previous weeks close.
Johnson & Johnson (JNJ) : The most positive equity analysts on Johnson & Johnson (JNJ) expects the shares to touch $142, whereas, the least positive believes that the stock will trade at $93 in the short term. The company is covered by 13 Wall Street Brokerage Firms. The average price target for shares are $123.39 with an expected fluctuation of $14.22 from the mean.
Johnson & Johnson (NYSE:JNJ): On Fridays trading session , Opening price of the stock was $125.12 with an intraday high of $125.35. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $124.645. However, the stock managed to close at $125.03, a loss of 0.10% for the day. On the previous day, the stock had closed at $125.15. The total traded volume of the day was 5,839,195 shares.
In a related news, The Securities and Exchange Commission has divulged that Pruden Gary J, officer (Exec VP, WW Chair, Med Devices) of Johnson & Johnson, had unloaded 9,735 shares at an average price of $116.03 in a transaction dated on June 7, 2016. The total value of the transaction was worth $1,129,552.
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.